Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-29
2008-11-18
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07452902
ABSTRACT:
In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyridine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 5574042 (1996-11-01), Oku et al.
patent: 2004/0018192 (2004-01-01), Wakabayashi et al.
patent: 0 673 937 (2003-11-01), None
patent: WO 96/34866 (1996-11-01), None
patent: WO 98/37080 (1998-08-01), None
patent: WO 99/55706 (1999-11-01), None
patent: WO 01/56607 (2001-08-01), None
patent: WO 02/20523 (2002-03-01), None
Gregory et al., Journal of Andrology, 2001, vol. 22, pp. 537-548.
Hand et al., J. Org. Chem., 1978, vol. 43, pp. 2900-2906.
Vesely et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”,Eur. J. Biochem.(1994), 224: 771-786.
Senderowicz et al., “Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasams”,Journal of Clinical Oncology(Sep. 1998), 16(9): 2986-2999.
Meijer et al., “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”,Eur. J. Biochem. (1997), 243: 527-536.
Bible et al., “Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”,Cancer Research(Aug. 15, 1997), 57: 3375-3380.
Shiota et al., “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine”,Chem. Pharm. Bull. (1999), 47(7): 928-938.
Yasuo Makisumi, “Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines.”,Chem. Pharm. Bull. (1962), 10: 620-626.
Diego Basso et al., “Synthetic Approach to Imidazo[1,2-a]pyridine Derivatives by the Intramolecular Nitrone Cycloaddition Methodology”, Tetrahedron, 58, 4445-4450 (2002).
E. Smakula Hand et al., “Teleamination of the Imidazo[1,2-a]pyridine System”, J. Org. Chem., 43(14), 2900-2906 (1978).
International Search Report for International Application No. PCT/US 03/29498, mailed Apr. 21, 2004 (5pgs.).
Doll Ronald J.
Dwyer Michael P.
Girijavallabhan Viyyoor M.
Guzi Timothy J.
Keertikar Kartik M.
Kalyanaraman Palaiyur S.
Rahmani Niloofar
Schering Corporation
Seaman D. Margaret
LandOfFree
Imidazopyridines as cyclin dependent kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazopyridines as cyclin dependent kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazopyridines as cyclin dependent kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042100